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Abstract  
Object:  
To quantify the periventricular venous density in neuromyelitis optica spectrum disease 
(NMOSD) in comparison to multiple sclerosis (MS) and healthy control subjects.  
 
Materials and Methods:  
Sixteen NMOSD, sixteen MS and sixteen healthy control subjects (HC) underwent 7.0 
Tesla (7T) MRI. The imaging protocol included T2* weighted (T2*w) fast low angle shot 
(FLASH) and fluid attenuated inversion recovery (FLAIR) sequences. The periventricular 
venous area (PVA) was manually determined by a blinded investigator in order to estimate 
the periventricular venous density in a region-of-interest based approach. 
 
Results:  
No significant differences in periventricular venous density indicated by PVA were 
detectable in NMOSD versus healthy controls (p=0.226). In contrast, PVA was significantly 
reduced in MS patients compared to HC (p=0.013). 
 
Conclusion:  
Unlike in MS, patients suffering from NMOSD did not show a reduced venous visibility. 
This finding may underscore primary and secondary pathophysiological differences 
between these two distinct diseases of the central nervous system.  
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Introduction 
Neuromyelitis optica spectrum disorders (NMOSD) are often disabling neuroinflammatory, 
autoimmune central nervous system conditions predominantly affecting the spinal cords 
and optic nerves [1–4]. Prior to the discovery of a serum immunoglobulin G antibody 
targeting the aquaporine-4 water channel [5, 6], it was often considered a variant of 
multiple sclerosis (MS) as the clinical presentation of these two distinct central nervous 
system (CNS) diseases may overlap [1]. Indeed, patients with NMOSD are still often 
misdiagnosed with MS in clinical practice [7, 8].  
Magnetic resonance imaging has improved our pathophysiological understanding of 
various CNS diseases. Driven by the improvements of gradient echo MRI techniques [9], 
intracranial veins can now be studied in vivo at 1.5 Tesla (T) and 3T, e.g. applying three 
dimensional (3D) susceptibility weighted imaging (SWI).   
Gaining from an increased signal-to-noise ratio, increased susceptibility effects, and hence 
an increased sensitivity to venous deoxyhemoglobin concentration, ultrahigh field MRI at 
7T advanced the visualization of even small intracranial veins [10, 11], improving the 
characterization of brain lesions, and facilitating the differentiation between MS and 
NMOSD [12, 13]. In MS, a reduced visibility of the cerebral venous system was reported 
recently [14, 15]. The reason for diminished visibility of the venous vasculature on 7T T2*w 
images in MS remains to be clarified. It may result from a reduced oxygen consumption as 
consequence of a widespread cerebral gliosis and hypometabolic state, leading to a 
reduced deoxygenation of the brain’s venous blood and thus less susceptibility related 
signal loss on T2*w images [14, 15].  
It is not known whether venous density is altered in NMOSD. Our work aimed at 
quantifying periventricular venous density in NMOSD including a careful comparison 
between healthy control subjects, NMOSD and MS patients.   
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Materials and Methods 
Study participants 
A synopsis of the demographical and clinical details is presented in Table 1. Sixteen 
NMOSD patients underwent ultrahigh field MRI at 7T. All NMOSD patients were 
seropositive for aquaporine-4-IgG. Inclusion criteria were diagnosis of NMOSD as defined 
by the current international consensus diagnostic criteria for NMOSD [1], age of at least 18 
years, and no contraindications to 7T MRI. Sixteen patients with relapsing-remitting MS as 
defined by the current panel criteria [16], and sixteen age-matched healthy control subjects 
that were most comparable to the NMOSD cohort regarding gender, age and – if 
applicable - disease duration were selected from a research database of the NeuroCure 
Clinical Research Center (NCRC). Neurological disability was assessed with the Kurtzke 
Expanded Disability Status Scale (EDSS) [17]. The study was approved by the local ethics 
committee. Written informed consent was obtained from all subjects prior to the study. 
 
MRI data acquisition 
Ultrahigh field magnetic resonance images were acquired using a 7T whole-body MR 
system (Magnetom, Siemens, Erlangen, Germany) and a 24-channel RF head coil (Nova 
Medical, Wilmington, MA, USA).  
The imaging protocol included:  
- two-dimensional axial T2*w fast low angle shot acquisitions (FLASH, TE=25.0ms; 
TR=1820ms; flip angle=35°; spatial resolution=(0.5×0.5)mm2, slice thickness 2mm, 
supratentorial brain coverage) and 
- fluid attenuated inversion recovery acquisitions (FLAIR; TE=90ms; TR=16000ms; 
TI=2925.5ms, spatial resolution (1.0×1.0)mm2, slice thickness 3mm, whole brain 
coverage). 
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Image analysis 
Images were analysed using the OsiriX software package (version 3.8.1. Osirix 
Foundation, Genève, Switzerland) by an investigator (SS) blinded to clinical data 
(diagnosis, disease duration, EDSS). To estimate the periventricular venous density, we 
decided to use a manual approach since signal inhomogeneities on 7T T2*w images 
impact automated segmentation procedures. The periventricular vascular area (PVA) was 
assessed as described previously (Figure 1) [14]. In brief, a minimal intensity projection 
map (MIP) of the two adjacent axial T2*w slices that are tangential to the roof of the lateral 
ventricles was calculated first. This procedure eliminates the risk of double counting 
venous voxel in two neighbouring slices, and improves the visibility of venous structures. 
Next, a squared region of interest (ROI) with a length of 4cm and a width of 1cm was 
defined for both brain hemispheres and positioned in between the frontal and occipital 
horns. The investigator then manually marked each venous voxel with a signal intensity of 
less than 10% of the mean signal intensity of the neighbouring normal appearing vein-free 
white matter. The applied 10% threshold builds on previous reports [14]. To determine the 
mean signal intensity of the neighbouring normal appearing vein-free white matter, multiple 
ellipsoid ROIs with an area of 2mm2 were used as a reference. Finally, the PVA (in mm2) 
was calculated as the sum of all venous voxel.  
The left hemisphere of one MS patient was excluded from analyses due to previous brain 
biopsy in this area. Lesion count was conducted in a separate analysis of the FLAIR 
images. A lesion was defined as a hyperintensity relative to the surrounding normal-
appearing white or grey matter with a diameter of at least 3mm. 
 
Statistical analysis 
All analyses were performed by using IBM SPSS Statistics (version 22, IBM, Somers, NY, 
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USA). P-values <0.05 were considered significant. Group differences in gender were 
analysed by using a Chi-squared test. Group differences in PVA and age between MS, 
NMOSD and healthy control subjects were assessed using a parametric Student´s t-test. 
Normality of PVA and age was previously assessed by using a visual analysis and the 
Shapiro-Wilk test (PVA, p=0.931; age, p=0.188). Group differences in lesion count, time 
since first symptoms and EDSS were assessed by using a non-parametric Mann-Whitney 
U test since these variables were not normally distributed (Shapiro-Wilk, lesion count, 
p<0.001; time since first symptoms, p<0.001; EDSS, p=0.043). Thus, associations 
between lesion count and PVA were assessed using non-parametric Spearman correlation. 
Statistical dependencies between age and PVA were assessed using parametric Pearson 
correlation. Finally, gender differences in PVA were analysed by using a Mann-Whitney U 
test. 
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Results 
In total, we detected 118 (mean±SD, range; 7±10, 0-38) cerebral FLAIR hyperintense 
white matter lesions in 12 of 16 NMOSD patients and 355 (mean±SD, range; 22±19, 0-65) 
cerebral white matter lesions in 15 of 16 MS patients. A total number of 112 (mean±SD, 
range; 7±13, 0-42) white matter lesions were seen in 9 of 16 healthy control subjects. 
These lesions in HC were non-specific in appearance and potentially related to small 
vessel disease in a subgroup of older healthy control subjects.  
Visual inspection of 7T T2*w images shows the periventricular venous system to be 
altered in MS patients as compared to healthy controls. In contrast, no obvious differences 
were apparent when NMOSD patients were compared versus healthy control subjects. To 
highlight these findings Figure 2 shows T2*w images deduced from exemplary MS and 
NMOSD patients. 
Periventricular vascular area in healthy control subjects, NMOSD and MS patients 
In healthy control subjects, mean PVA was 144mm2 (SD 27mm2, range 92-202mm2). PVA 
was not associated with gender in healthy control subjects (p=0.713), which is in 
agreement with previous published results [14]. However, we observed a trend towards 
smaller PVA values in older healthy control subjects (r=-0.458, p=0.074).  
When comparing NMOSD patients with healthy control subjects, we did not observe any 
differences in PVA (NMOSD, mean±SD, range; 133±21, 98-170 mm2, p=0.226,) as 
outlined in Figure 3. In contrast, PVA was significantly reduced in MS (mean±SD, range; 
117±30, 61-173 mm2) compared to healthy control subjects (p=0.013, Figure 3). There 
was a trend towards smaller PVA in MS versus NMOSD (p=0.090).  
Associations with lesion count 
Finally, we asked whether these differences in periventricular venous density could be due 
to group differences in lesion count since the periventricular venous visibility was reported 
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to be inversely correlated with the number of T2w lesions in MS patients.[14] Indeed, we 
observed an inverse correlation between the lesion count and PVA in our MS group (rs= -
0.555, p=0.026). No such an association was seen in patients with NMOSD (rs=0.120, 
p=0.658).  
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Discussion 
Increased spatial resolution and susceptibility effects of ultrahigh field MRI at 7T allow for 
markedly improved visualization of the brain’s venous system. We have taken advantage 
of these capabilities to analyze the periventricular venous system in NMOSD in 
comparison to MS and healthy volunteers. While the periventricular venous visibility was 
diminished in MS compared to both NMOSD and healthy controls, there was no significant 
difference between venous density in NMOSD versus healthy volunteers.  
To interpret our findings, one has to consider the cause of the superb visibility of venous 
structures in 7T T2*w or susceptibility weighted images: Deoxygenated haemoglobin is a 
compound with paramagnetic properties leading to susceptibility-related signal loss in 
gradient echo MR images. In contrast, oxygenated haemoglobin is diamagnetic. Thus, the 
venous visibility is highly dependent on the degree of (de-)oxygenation. Other factors, 
such as the velocity of the venous blood flow or the size of the venous vessel could also 
impact the visibility of veins on T2*w images.  
Recently, various studies in MS patients identified changes in the visibility of small veins 
on T2*w images [14, 15]. The diminished visibility of the veins in MS may be due to a 
widespread cerebral hypometabolic state as a result of neurodegeneration in MS. This  
leads to a reduced deoxygenation of the brain’s venous blood and, consequently, less 
susceptibility-related signal loss on T2*w images [14, 15]. This hypothesis is further 
supported by a quantitative MRI study that reported significantly increased venous 
oxygenation levels and decreased cerebral metabolic rates of oxygen in MS patients as 
compared with healthy controls [18]. Furthermore, vascular damage, a sequel of 
(perivascular) inflammation and gliosis [19] in MS, is associated with a globally reduced 
cerebral perfusion [20] and may thus contribute to diminished venous visibility on T2*w 
images [14, 15]. Another possible cause of decreased oxygen uptake is the high level of 
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nitric oxide (NO) due to repetitive vascular inflammation in MS competitively inhibiting 
mitochondrial uptake of oxygen in MS [18].  
In contradistinction to MS, venous density in NMOSD patients was found to be similar to 
that in healthy controls. The comprehensive interpretation of this finding remains 
controversial. One valuable hypothesis is that brain damage and neurodegeneration is – in 
contrast to MS – less severe and more focal in nature in NMOSD patients. Therefore, 
cerebral hypometabolism seen in MS may not be a feature of NMOSD, or may be present 
to much lesser extent. This could potentially explain normal measures of venous density in 
NMOSD.  
Whether, and to what extent diffuse brain damage occurs in NMOSD is a matter of 
controversy [21–25]. On the one hand, studies using volumetrics [23], spectroscopy [22], 
and diffusion tensor imaging (DTI) [24] have shown that diffuse brain atrophy in NMOSD is 
less pronounced than in MS, or even similar to healthy control subjects. Other studies 
identified widespread brain alterations in NMOSD [21, 26]. These changes were, however, 
less severe than in MS, which is in line with our results showing a weak trend of smaller 
PVA values in NMOSD versus healthy volunteers.  
Venous density in NMOSD was – in contrast to MS – not associated with the number of 
brain lesions in our study. This discrepancy might be a consequence of more diffuse 
structural damage such as brain parenchymal gliosis in MS versus NMOSD, that causes 
decreased PVA in MS. 
A limitation of this study that assessed the periventricular venous density by using a 
manual approach is the small sample size of the cohort respective low power in detecting 
subtle vascular changes. Although all images were anonymized, blinding to the MS 
diagnosis was not always achievable as a consequence of the existence of lesions 
strongly suggestive of MS. Minor motion artefacts may have also biased our results. 
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Despite the absence of any gender differences in PVA in healthy control subjects, we 
cannot exclude that gender differences between NMOSD and healthy control subjects 
have influenced our results.  
 
Conclusion 
 
In conclusion, the periventricular venous system appeared similar in NMOSD and healthy 
controls on 7T T2*w images. This finding is in contrast to MS and may highlight 
pathogenetic differences between these distinct autoimmune neuroinflammatory disease 
entities.  
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Tables and Figures 
 
 
Figure 1. Method of analysis.  A minimal intensity projection map of two T2*w image 
slices of an exemplary healthy control is presented. The blinded investigator masked each 
venous voxel (red area) in two squared regions of interest (ROIs, green box) as described 
in the methods section. 
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Figure 2. Periventricular venous density in a healthy control, and an exemplary 
NMOSD and MS patient. 
7T T2*w FLASH visualizes a normal periventricular venous density in HC and NMOSD, 
but a moderately decreased periventricular venous vasculature in MS. 
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Figure 3. Plot. No statistically significant differences in periventricular venous density 
indicated by PVA were detectable between patients with NMOSD and healthy volunteers.   
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Table 1. Demographical details.  
 Healthy controls MS NMOSD 
N 16 16 16 
Gender [n, female] 6 11 
p=0.077& 
16 
p<0.001& 
Age mean±SD, range 
[years] 
45±15, 20-70 43±8, 26-53  
p=0.608& 
48±15, 22-70 
p=0.633& 
Time since first 
symptoms mean±SD, 
range [years] 
- 7.5±6.9, 0.5-25.4 9.5±9.3, 1.8-34.1 
p=0.515# 
EDSS median, range - 1.75, 0-4.5 3.0, 1.5-6.0 
p=0.086# 
Lesion count mean±SD, 
range 
7±13, 0-42 22±19, 0-65 
p=0.002& 
7±10, 0-38 
p=0.341& 
PVA mean±SD, range 
[mm2] 
144±27, 92-202 117±30, 61-173 
p=0.013& 
133±21, 98-170 
p=0.226& 
 
Key: PVA periventricular vascular area, & p-values express differences between healthy 
volunteers and MS or healthy volunteers and NMOSD patients. # p-values express 
differences between MS and NMOSD patients. 
